Skip to content

Assessment of clinical features and immune status of patients with chikungunya

Assessment of clinical features and immune status of patients with chikungunya

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600116473
Enrollment
Unknown
Registered
2026-01-11
Start date
2025-07-19
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CHIKV infection

Interventions

Observation group:None

Sponsors

The First People's Hospital of Foshan
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Voluntarily signed informed consent; 2.Age>=18 years old, male or female; 3.Including recent travel to chikungunya-endemic areas, places of residence or work, chikungunya fever cases, fever, muscular and osteoarthralgia, headache and rash, living in chikungunya-endemic areas or travel to endemic areas within 12 days, and history of mosquito bites within 12 days before the onset of symptoms; 4.The laboratory diagnosis criteria are consistent with the clinical case of chikungunya fever, positive detection of chikungunya virus nucleic acid, or positive chikungunya virus antibody, or isolation of virus, or the titer of serum-specific IgG antibodies in the convalescent phase is more than 4 times higher than that in the acute phase; 5.Subject is voluntary and able to comply with all requirements specified in the study protocol.

Exclusion criteria

Exclusion criteria: 1.suspected focal infection; 2.Subject has other pre-existing medical conditions that may preclude compliance with the various evaluation plans in the treatment protocol, or may interfere with the observation of the efficacy or safety of this study (e.g., current malignancy, uncontrolled seizures, severe psychiatric illness, active tuberculosis currently being treated, etc.); 3.Age < 18 years, pregnant women; 4.Patients who are judged by the investigator to be unsuitable to participate in this trial;

Design outcomes

Primary

MeasureTime frame
Subjects' Clinical Characteristics, Virological Characteristics, and Immunological Characteristics;

Secondary

MeasureTime frame
Subjects' chronic arthropathies and joint sequelae at 1 month, 2 months, and 6 months post-discharge.;Safety indicators during follow-up, including the incidence of adverse events and abnormal clinical laboratory findings.;

Countries

China

Contacts

Public ContactHonglian Bai

The First People's Hospital of Foshan

bhlfsyy@163.com+86 757 8316 1862

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026